COVERAGE FOR CONTINUOUS GLUCOSE MONITORING

Did you know that coverage for CGM continues to grow? 

You may be eligible for Medtronic continuous glucose monitoring (CGM) under your provincial program or through your insurance plan, giving you access to our integrated insulin pump- including our MiniMed™ 770G SystemMiniMed™ 670G System or our standalone Guardian™ Connect  CGM system (Guardian Connect)**. 

 

YT
AB
SK
MB
Hotspot 5
PEI
Other
Hotspot 8
Hotspot 9
Hotspot 10
Hotspot 11
Hotspot 12

Click on the province you live in to learn more about the reimbursement coverage available.

PEI Coverage 

Expand All

Who:

What:

How:

Ontario Coverage 

Expand All

Who:

What:

How:

MANITOBA Coverage

Expand All

Who:

What:

How:

SASKATCHEWAN COVERAGE 

Expand All

Who:

What:

How:

ALBERTA COVERAGE 

Expand All

Who:

What:

How:

Yukon COVERAGE 

Expand All

Who:

What:

How:

NIHB COVERAGE 

Expand All

Who:

What:

How:

Other COVERAGE 

CGM coverage continues to change. We’ll continue to keep this page updated. You may also have coverage through your private insurance or be eligible for our CGM Access Program. 

PRIVATE INSURANCE:  CGM is a standard benefit for many insurance providers and your coverage could vary depending on your plan. Medtronic can help you determine your coverage at no extra cost. Give us a call at 1.800.284.4416 or complete the form below.  

MEDTRONIC CGM ACCESS PROGRAM: We understand our SmartGuard™ technology can help you with your diabetes management. If you don’t have coverage for Medtronic CGM, we may be able to help. You may be eligible to access CGM for $99 per month.* Give us a call to find out more at 1.800.284.4416

*Terms and conditions apply to this program. Program subject to change at any time.  

 

 

HAVE QUESTIONS ABOUT YOUR COVERAGE? 

Whether you need help understanding your provincial coverage or to check your private insurance, we are here to help. 

Fill out the form below or give us a call at 1.800.284.4416. 

By submitting this form you are consenting to and confirm the following:

  • That Medtronic can communicate with you regarding our diabetes products by telephone, fax, mail and/or e-mail.
  • That Medtronic stores information, including personal health information, on systems located outside of Canada.
  • That you have read and are aware of our privacy policy.
  • That you grant Medtronic of Canada permission to send you updates on diabetes and diabetes technology.
  • You may revoke this permission at any time by emailing medtronicdiabetescc@medtronic.com
  • Medtronic respects the confidentiality of personal information. We assure you we will not share your personal information, except as otherwise noted in our privacy policy.


We expect to get back to you within five business days

learn more about insulin pumps

Learn more about the MiniMedTM 770G system.

LEARN MORE
770G System

learn more about cgm

Learn more about Guardian ConnectTM

LEARN MORE

IMPORTANT SAFETY INFORMATION

**GUARDIAN™ CONNECT CGM SYSTEM

  • Do not use the Guardian Connect System for pediatric patients until you have thoroughly reviewed (with your Healthcare Professional), the system alert performance in the Guardian Connect Application User Guide and the sensor accuracy performance in the Guardian Sensor (3) Performance document. Discuss with your Healthcare Professional how to best set up your Guardian Connect System alerts to reduce the risk of missing low blood glucose or high blood glucose events.
  • In the pediatric clinical study (3-18 years of age), larger differences were observed between the Guardian Connect System and actual blood glucose values compared to those differences observed in the adolescent/adult clinical study (14-75 years of age), particularly at low glucose levels.
  • In the pediatric clinical study, a significant percentage of low glucose events were not detected by the Guardian Connect System. Do not rely solely on the Guardian Connect System alerts to detect low glucose.
  • In the pediatric clinical study, the Guardian Connect System triggered a high percentage of false low glucose and false high glucose alerts. The Guardian Connect System is not intended to make therapy adjustments: always check your capillary blood glucose before making therapy adjustments.
  • In the pediatric clinical study, enabling the ‘Alert Before Low’ and ‘Alert Before High’ predicted alerts significantly reduced the percentage of missed low blood glucose and missed high blood glucose events, but also significantly increased the percentage of false low glucose and false high glucose alerts. Do not ignore alerts from your Guardian Connect System. Always follow your treatment instructions from your Healthcare Professional when responding to an alert from your Guardian Connect System.

As of December 7, 2020. The MiniMed™ 770G is indicated for people living with Type 1 diabetes, ages 2 and older.   Individual results may vary. Some user interaction required.